Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
The antigenic evolution of SARS-CoV-2 requires ongoing monitoring to judge the immune escape of newly arising variants. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal sera. We compared 18 datasets generated using human, hamster, and mouse sera, and six different neutralization assays. Titer magnitude was lowest in human, intermediate in hamster, and highest in mouse sera. Fold change, immunodominance patterns and antigenic maps were similar among sera. Most assays yielded similar results, except for differences in fold change in cytopathic effect assays. Not enough data was available for conclusively judging mouse sera, but hamster sera were a consistent surrogate for human first-infection sera.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2023) vom: 27. Sept. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.09.27.559689 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363018611 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363018611 | ||
| 003 | DE-627 | ||
| 005 | 20240210232720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.09.27.559689 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1286.xml |
| 035 | |a (DE-627)NLM363018611 | ||
| 035 | |a (NLM)37808679 | ||
| 035 | |a (PII)2023.09.27.559689 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mühlemann, Barbara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The antigenic evolution of SARS-CoV-2 requires ongoing monitoring to judge the immune escape of newly arising variants. A surveillance system necessitates an understanding of differences in neutralization titers measured in different assays and using human and animal sera. We compared 18 datasets generated using human, hamster, and mouse sera, and six different neutralization assays. Titer magnitude was lowest in human, intermediate in hamster, and highest in mouse sera. Fold change, immunodominance patterns and antigenic maps were similar among sera. Most assays yielded similar results, except for differences in fold change in cytopathic effect assays. Not enough data was available for conclusively judging mouse sera, but hamster sera were a consistent surrogate for human first-infection sera | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Wilks, Samuel H |e verfasserin |4 aut | |
| 700 | 1 | |a Baracco, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Bekliz, Meriem |e verfasserin |4 aut | |
| 700 | 1 | |a Carreño, Juan Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Corman, Victor M |e verfasserin |4 aut | |
| 700 | 1 | |a Davis-Gardner, Meredith E |e verfasserin |4 aut | |
| 700 | 1 | |a Dejnirattisai, Wanwisa |e verfasserin |4 aut | |
| 700 | 1 | |a Diamond, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a Douek, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Drosten, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Eckerle, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Edara, Venkata-Viswanadh |e verfasserin |4 aut | |
| 700 | 1 | |a Ellis, Madison |e verfasserin |4 aut | |
| 700 | 1 | |a Fouchier, Ron A M |e verfasserin |4 aut | |
| 700 | 1 | |a Frieman, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Godbole, Sucheta |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart |e verfasserin |4 aut | |
| 700 | 1 | |a Halfmann, Peter J |e verfasserin |4 aut | |
| 700 | 1 | |a Henry, Amy R |e verfasserin |4 aut | |
| 700 | 1 | |a Jones, Terry C |e verfasserin |4 aut | |
| 700 | 1 | |a Katzelnick, Leah C |e verfasserin |4 aut | |
| 700 | 1 | |a Kawaoka, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Kimpel, Janine |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Lai, Lilin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Lusvarghi, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
| 700 | 1 | |a Montefiori, David C |e verfasserin |4 aut | |
| 700 | 1 | |a Mykytyn, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Netzl, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Pollett, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Rössler, Annika |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Xiaoying |e verfasserin |4 aut | |
| 700 | 1 | |a Sigal, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Subramanian, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Supasa, Piyada |e verfasserin |4 aut | |
| 700 | 1 | |a Suthar, Mehul |e verfasserin |4 aut | |
| 700 | 1 | |a Türeli, Sina |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Weiss, Carol D |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Derek J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2023) vom: 27. Sept. |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.09.27.559689 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 09 | ||